ACI-19626 (TDP-43 PET Tracer)
Diagnostic for TDP-43 proteinopathies
PreclinicalActive - Data published in Nature Communications
Key Facts
Indication
Diagnostic for TDP-43 proteinopathies
Phase
Preclinical
Status
Active - Data published in Nature Communications
Company
About AC Immune
AC Immune's mission is to diagnose, treat, and prevent neurodegenerative diseases through a precision medicine approach. The company has achieved significant validation through high-value partnerships with major pharmaceutical firms like Takeda, Janssen, and Lilly, and its pipeline features promising Phase 2 candidates in Alzheimer's and Parkinson's disease. Its strategy balances internal R&D of first- and best-in-class candidates with strategic collaborations that provide non-dilutive funding and de-risk development.
View full company profile